136 related articles for article (PubMed ID: 31186177)
1. Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.
Reza M; Wirth M; Tammela T; Cicalese V; Veiga FG; Mulders P; Miller K; Tubaro A; Debruyne F; Patel A; Caris C; Witjes W; Thorsson O; Wollmer P; Edenbrandt L; Ohlsson M; Trägårdh E; Bjartell A
Eur Urol Oncol; 2021 Feb; 4(1):49-55. PubMed ID: 31186177
[TBL] [Abstract][Full Text] [Related]
2. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
[TBL] [Abstract][Full Text] [Related]
3. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
4. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
5. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer.
Mitsui Y; Shiina H; Yamamoto Y; Haramoto M; Arichi N; Yasumoto H; Kitagaki H; Igawa M
BJU Int; 2012 Dec; 110(11 Pt B):E628-34. PubMed ID: 22788759
[TBL] [Abstract][Full Text] [Related]
6. Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.
Haupt F; Berding G; Namazian A; Wilke F; Böker A; Merseburger A; Geworski L; Kuczyk MA; Bengel FM; Peters I
Adv Ther; 2017 Apr; 34(4):986-994. PubMed ID: 28265811
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
Uemura K; Miyoshi Y; Kawahara T; Ryosuke J; Yamashita D; Yoneyama S; Yokomizo Y; Kobayashi K; Kishida T; Yao M; Uemura H
BMC Cancer; 2018 May; 18(1):501. PubMed ID: 29716525
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
[TBL] [Abstract][Full Text] [Related]
9. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
[TBL] [Abstract][Full Text] [Related]
10. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.
Reza M; Ohlsson M; Kaboteh R; Anand A; Franck-Lissbrant I; Damber JE; Widmark A; Thellenberg-Karlsson C; Budäus L; Steuber T; Eichenauer T; Wollmer P; Edenbrandt L; Trägårdh E; Bjartell A
Eur Urol Focus; 2016 Dec; 2(5):540-546. PubMed ID: 28723520
[TBL] [Abstract][Full Text] [Related]
11. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial.
Kitajima K; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Sasaki R; Narita M; Yamakado K
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345121
[TBL] [Abstract][Full Text] [Related]
12. Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer.
Anand A; Heller G; Fox J; Danila DC; Bjartell A; Edenbrandt L; Larson SM; Scher HI; Morris MJ
Clin Genitourin Cancer; 2022 Jun; 20(3):270-277. PubMed ID: 35279418
[TBL] [Abstract][Full Text] [Related]
13. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.
Mota JM; Armstrong AJ; Larson SM; Fox JJ; Morris MJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):522-530. PubMed ID: 31036925
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Automated Bone Scan Index as Predictors of Survival in Prostate Cancer.
Wiyanto J; Shintawati R; Darmawan B; Hidayat B; Kartamihardja AHS
World J Nucl Med; 2017; 16(4):266-270. PubMed ID: 29033673
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
BMC Cancer; 2016 Feb; 16():128. PubMed ID: 26896160
[TBL] [Abstract][Full Text] [Related]
17. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
19.
Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]